Inactive Instrument

Strongbridge Biopharma

Equities

SBBP

IE00BYZ5XL97

Strongbridge Biopharma plc Announces Appointment of Jeffrey W. Sherman to Board of Directors

October 03, 2016 at 05:30 pm IST

Strongbridge Biopharma plc announced that Jeffrey W. Sherman, M.D., FACP, chief medical officer and executive vice president of research and development at Horizon Pharma plc, has been appointed to its board of directors. Dr. Sherman has more than 25 years of research, clinical development, regulatory and commercialization experience within the biopharmaceutical industry.

Latest news about Strongbridge Biopharma

Strongbridge Biopharma plc(NasdaqGS:SBBP) dropped from S&P Global BMI Index	07/21/07	CI
Strongbridge Biopharma plc(NasdaqGS:SBBP) dropped from S&P TMI Index	07/21/07	CI
Strongbridge Biopharma plc(NasdaqGS:SBBP) dropped from NASDAQ Composite Index	05/21/05	CI
Xeris Pharmaceuticals, Inc. completed the acquisition of Strongbridge Biopharma plc from HealthCap VI L.P., a fund managed by Odlander, Fredrikson & Co. AB, Caxton Alternative Management LP, and others.	05/21/05	CI
Xeris Pharmaceuticals : Shareholders Approve Pending Strongbridge Biopharma Acquisition	15/21/15	MT
Strongbridge Biopharma : Says Glass Lewis Recommends Shareholders Vote in Favor of Proposed Deal with Xeris	31/21/31	MT
Xeris Pharmaceuticals : ISS Recommends Xeris, Strongbridge Shareholders Vote in Favor of Proposed Deal	30/21/30	MT
Strongbridge Biopharma : Earnings Flash (SBBP) STRONGBRIDGE BIOPHARMA Reports Q2 Loss $-0.07, vs. Street Est of $-0.10	05/21/05	MT
Strongbridge Biopharma : Earnings Flash (SBBP) STRONGBRIDGE BIOPHARMA Posts Q2 Revenue $10M, vs. Street Est of $8.89M	05/21/05	MT
Strongbridge Biopharma plc Revises KEVEYIS Revenue Guidance for the Full Year 2021	05/21/05	CI
Strongbridge Biopharma plc Announces Publication of Long-Term Efficacy and Safety Results for Keveyis® (Dichlorphenamide) for the Treatment of Primary Periodic Paralysis in Muscle & Nerve	13/21/13	CI
Insider Trends: Insider at Strongbridge Biopharma Makes Tax Sale Extends 90-Day Selling Trend	08/21/08	MT
Strongbridge Biopharma plc(NasdaqGS:SBBP) dropped from Russell 2000 Value Index	25/21/25	CI
Strongbridge Biopharma plc(NasdaqGS:SBBP) dropped from Russell 2000 Growth Index	25/21/25	CI
Strongbridge Biopharma plc(NasdaqGS:SBBP) dropped from Russell Small Cap Comp Value Index	25/21/25	CI
Strongbridge Biopharma plc(NasdaqGS:SBBP) dropped from Russell Small Cap Completeness Index	25/21/25	CI
Strongbridge Biopharma plc(NasdaqGS:SBBP) dropped from Russell Small Cap Comp Growth Index	25/21/25	CI
Strongbridge Biopharma plc(NasdaqGS:SBBP) dropped from Russell 2500 Value Index	25/21/25	CI
Strongbridge Biopharma plc(NasdaqGS:SBBP) dropped from Russell 3000 Growth Index	25/21/25	CI
Strongbridge Biopharma plc(NasdaqGS:SBBP) dropped from Russell 3000 Value Index	25/21/25	CI
Strongbridge Biopharma plc(NasdaqGS:SBBP) dropped from Russell 2500 Growth Index	25/21/25	CI
Strongbridge Biopharma plc(NasdaqGS:SBBP) dropped from Russell 3000E Value Index	25/21/25	CI
Strongbridge Biopharma plc(NasdaqGS:SBBP) dropped from Russell 3000E Index	25/21/25	CI
Strongbridge Biopharma plc(NasdaqGS:SBBP) dropped from Russell Microcap Value Index	25/21/25	CI
Strongbridge Biopharma plc(NasdaqGS:SBBP) dropped from Russell 2000 Index	25/21/25	CI

Chart Strongbridge Biopharma

Duration

Period

More charts

Company Profile

Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company's commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis. The United States Food and Drug Administration (FDA) has granted orphan drug designation for KEVEYIS. The Company has a clinical-stage pipeline of therapies for endocrine diseases. The Company's lead compounds include COR-003 (levoketoconazole), a cortisol synthesis inhibitor, and COR-005 (veldoreotide), a somatostatin analog (SSA). The Company is studying COR-003 for the treatment of endogenous Cushing's syndrome. It is investigating COR-005 for the treatment of acromegaly. Both COR-003 and COR-005 have received orphan designation from the FDA and the European Medicines Agency (EMA).

Sector

More about the company